Saturday, March 30, 2013

schedule-m PART I GOOD MANUFACTURING PRACTICES FOR PREMISES AND MATERIALS

According to the schedule M guidelines

Construction of building;

The factory building(s) for manufacture of drugs shall be so situated and shall have such measures as to avoid risk of contamination. Including open sewage, drain, public lavatory or any factory which produces disagreeable or obnoxious, odor, fumes, excessive soot, dust, smoke, chemical or biological emanations. Building(s) should be air conditioned where prescribed for the operations and dosage forms. The designed / constructed / maintained to prevent entry of insects, pests, birds, vermin and rodents. The building(s) used for the factory shall be designed, constructed, adapted and maintained to suit the manufacturing operations so as to permit production of drugs under hygienic conditions. They shall conform to the conditions laid down in the Factories Act, 1948 (63 of 1948).

Water supply

Water (as per the specifications of Pharmacopoeia) shall only be used for all the operations except washing and cleaning operations where potable water may be used. Water shall be stored in tanks, which do not adversely affect quality of water and ensure freedom from microbiological growth. The tank shall be cleaned periodically and records maintained by the licensee in this behalf.

Disposal of water ;

Disposal of sewage and effluents (solid, liquid and gas) from the manufactory shall be in conformity with the requirements of Environment Pollution Control Board (EPCB). All bio-medical waste shall be destroyed as per the provisions of the Rio Medical Waste (Management and Handling) Rules, 1996.

Production area;

The production area shall be designed to allow the production preferably in uni-flow and with logical sequence of operations. In order to avoid the risk of cross-contamination, separate dedicated and self-contained facilities shall be made available for the production of sensitive pharmaceutical products like penicillin or biological preparations with live microorganisms.

Quality control;

Quality-Control Laboratories shall be independent of the production areas. Separate areas shall be provided each for physicochemical, biological, microbiological or radio-isotope analysis. Quality Control Laboratories shall be designed appropriately for the operations to he carried out in them.

Ancillary area

Rest and refreshment rooms shall he separate from other areas. These areas shall not lead directly to the manufacturing and storage areas. Facilities for changing storing clothes and for washing and toilet purposes shall be easily accessible and adequate for the number of users. Toilets separate for males and females, shall not be directly connected with production or storage areas.

Warehousing area

Adequate areas shall be designed to allow sufficient and orderly warehousing of various categories of materials and products like starting and packaging materials intermediates bulk and finished products, products in quarantine released, rejected, returned or recalled machine and equipment spare parts and change items.

Health clothing and sanitation of workers

The personnel handling Beta-lactam antibiotics shall be tested for Penicillin sensitivity before employment and those handling sex hormones, cytotoxic substances and other potent drugs shall he periodically examined for adverse effects Smoking. Eating, drinking, chewing or keeping plants, food, drink and personal medicines shall not be permitted in production. All employees shall be instructed to report about their illness or abnormal health condition to their immediate supervisor so that appropriate action can be taken.

Manufaturing operations and controls

The contents of all vessels and containers used in manufacture and storage during the various manufacturing stages shall be conspicuously labeled with the name of the product, batch no, batch size and stage of manufacture. Each label should be initialed and dated by the authorized
technical staff.

Raw materials

There shall be adequate separate areas for materials "under test", "approved ", and "rejected" with arrangements and equipment to allow dry, clean and orderly placement of stored materials and products, wherever necessary. Under controlled temperature and humidity. All incoming materials shall be quarantined immediately after receipt or processing. All materials shall be conditions and in an orderly fashion to permit hatch segregation and stock rotation by a 'first in/first expiry' - 'first-out' principle.

Documentation and records

Documentation is an essential part of the Quality assurance system and, as such, shall be related to all aspects of Good Manufacturing Practices (GMP). Its aim is to define the specifications for all materials, method of manufacture and control, to ensure that all personnel concerned with manufacture know the information necessary to decide whether or not to release a batch or drug for sale and-to provide an audit trail that shall permit investigation of the history of any suspected defective batch. Records and associated Standard Operating Procedures (SOP) shall be retained for at least one year after the expiry date of the finished product. Data may be recorded by electronic data processing systems or other reliable means, but Master Formulae and detailed operating procedures relating to the system in use shall also be available in a hard
copy to facilitate checking of the accuracy of the records.

Labels and other printed materials

All containers and equipment shall hear appropriate labels. Different color coded labels shall be used to indicate the status of a product (for example under test, approved. passed, rejected). Prior to release, all labels for containers, cartons and boxes and all circulars, inserts and leaflets shall be examined by the Quality Control Department of the licensee.

Quality assurance

It is the totality of the arrangements made with the object of ensuring that products arc of the quality required for their intended use. The finished product is correctly processed and checked in accordance with established procedures. Every manufacturing establishment shall establish its own quality control laboratory manned by qualified and experienced staff. The area of the quality control laboratory may be divided into Chemical, Instrumentation Microbiological and Biological testing.

Specifications

For the various raw materials and packaging materials, containers, closures and finished products various specifications should be written on the labels and should be maintained in the records.
(a) The designated name of the product and the code reference
(b) The formula or a reference to the formula and the pharmacopoeial reference
(c) Directions for sampling and testing or a reference to procedures
(d) A description of the dosage form and package details
(e) The qualitative and quantitative requirements. With the acceptance limits for release
(f) The storage conditions and precautions where applicable, and
(g) The shelf-life.

Master formula records

There shall be Master Formula records relating to all manufacturing procedures for each product and batch size to be manufactured. These shall be prepared and endorsed by the competent technical staff. i.e. Head of production and quality control. It should include:
(a) The name of the product together with product reference code relating to its specifications
(b) The patent or proprietary name of the product along with the generic name, a description of the dosage form, strength, composition of the product and batch size
(c) Name, quantity, and reference number of all the starting materials to be used. Mention shall be made of any substance that may 'disappear' in the course of processing
(d) A statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable
(e) A statement of the processing location and the principal equipment to he used
(f) The methods. or reference to the methods, to be used for preparing the critical equipment including cleaning, assembling, calibrating, sterilizing
(g) Detailed stepwise processing instructions and the time taken for each step
(h) The instructions for in-process controls with their limits
(i) The requirements for storage conditions of the products, including the container, labeling and special storage conditions where applicable
(j) Any special precautions to be observed
(k) Packing details and specimen labels.

Batch packaging records

A batch packaging record shall be kept for each batch or part batch processed. It shall be based on the relevant parts of the packaging instructions and the method of preparation of such records shall be designed to avoid transcription errors.

Reference samples

Each lot of every active ingredient. in a quantity sufficient to carry out all the tests except sterility and pyrogens or Bacterial Endotoxin. Test shall be retained for a period of 3 months after the date of expiry of the last batch produced from that active ingredient.

Product recalls

A prompt and effective product recall system of defective products shall be devised for timely information of all concerned stockiest, wholesalers, suppliers, up to the retail level within the shortest period. The licensee may make use of both print and electronic media in this regard. There shall be an established written procedure in the form of Standard Operating Procedure for effective recall of products distributed by the licensee. Recall operations shall be capable of being initiated promptly so as to effectively reach at the level of each distribution channel.
Sterile products, being very critical and sensitive in nature, a very high degree of precautions, prevention and preparations are needed. Dampness, dirt and darkness are to be avoided to ensure aseptic conditions in all areas. There shall be strict compliance in the prescribed standards especially in the matter of supply of water, air, active materials and in the maintenance of hygienic environment. Air Handling Units for sterile product manufacturing areas shall be different from those for other areas. Critical areas, such as the aseptic filling area, sterilized components unloading area and change rooms conforming to Grades B, C and D respectively shall have separate Air Handling Units The filling operations shall take place under Grade A conditions which shall be demonstrated under working of simulated conditions which shall be achieved by providing Laminar Air flow work stations with suitable HEPA filters or isolator technology. There shall be a written environmental monitoring program and microbiological results shall be recorded. Recommended limits for microbiological monitoring of clean areas "in operation" are given.

PRINCIPLES OF SCHEDULE M

The first WHO draft text on GMP was prepared in 1967 by a group of consultants, at the request of the Twentieth World Health Assembly. The revised text was discussed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its twenty-second report.

Amendment to Schedule M, Drug and Cosmetics Act

The amendment of the Schedule M of India’s Drug & Cosmetics Act that came into effect in accordance with the WHO terms was more relaxed and far less stringent than the ones insisted by US or European drug regulators. Interestingly, many of the Indian pharm companies who export to regulated markets follow US FDA or MHRA of UK standards.

Issue of attenuation of schedule M

The Government has amended the Good Manufacturing Practices (GMP) outlined in Schedule M to the Drugs and Cosmetics Rules to ensure that manufacturing units comply with the WHO and international standards of production. Under the amended rules, it has been decided that the ancillary area requirements for plant and equipment for manufacture of majority of formulations have been deleted. Certain changes in the air handling system have also been made apart from certain other minor changes to streamline the requirements.

Revised Schedule M and its impact on SSIs

Abstract:-

Schedule M of Drug and Cosmetics Act deals with various requirements for the manufacturing of drugs and pharmaceuticals, which includes GMPs. GMPs stands for good manufacturing practice and they are essential for producing quality products. The current Schedule M is based on 1982 WHO GMP guidelines.

download guidelines

Pharma units to meet Schedule-M deadline Quality circles, FDCA help firms

A proactive Food and Drugs Control Administration (FDCA) and the formation of a co-operative of small pharmaceutical companies to help them upgrade facilities at their units have ensured that most of the small pharmaceutical companies will comply with the Schedule M guidelines of the Drugs and Cosmetics Act, the deadline for which is December 31, 2004. 

schedule-m guidelines

The Ministry of Health and Family Welfare has amended "Schedule M" to the Drugs and Cosmetics Rules, 1945 which relates to Good Manufacturing Practices (GMPs) 

Friday, March 29, 2013

ICH Stability Q1A - Q11



  • Stability Q1A - Q1F













    • Q1A(R2)Stability Testing of New Drug Substances and ProductsQ1A
    • Q1BStability Testing : Photostability Testing of New Drug Substances and Products
    • Q1CStability Testing for New Dosage Forms
    • Q1DBracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
    • Q1EEvaluation of Stability Data
    • Q1FStability Data Package for Registration Applications in Climatic Zones III and IV

     
    Analytical Validation Q2



    Q2(R1)Validation of Analytical Procedures: Text and MethodologyQ2A, Q2B
    Finalised Guidelines:
    October 1994/November 1996
    Description: The tripartite harmonised ICH Guideline on Text (previously coded Q2

    Impurities Q3A - Q3D



      • Q3A(R2)Impurities in New Drug Substances
      • Q3B(R2)Impurities in New Drug Products
      • Q3C(R5)Impurities: Guideline for Residual SolventsQ3C, Q3C(M)
      • Q3DImpurities: Guideline for Metal Impurities

    Pharmacopoeias Q4 - Q4B



      • Q4Pharmacopoeias
      • Q4APharmacopoeial Harmonisation
      • Q4BEvaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
      • Q4B Annex 1R1Residue on Ignition/Sulphated Ash General Chapter
      • Q4B Annex 2R1Test for Extractable Volume of Parenteral Preparations General Chapter
      • Q4B Annex 3R1Test for Particulate Contamination: Sub-Visible Particles General Chapter
      • Q4B Annex 4AR1Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter
      • Q4B Annex 4BR1Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-Organisms General Chapter
      • Q4B Annex 4CR1Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter
      • Q4B Annex 5R1Disintegration Test General Chapter
      • Q4B Annex 6R1Uniformity of Dosage Units General Chapter
      • Q4B Annex 7R2Dissolution Test General Chapter
      • Q4B Annex 8R1Sterility Test General Chapter
      • Q4B Annex 9R1Tablet Friability General Chapter
      • Q4B Annex 10R1Polyacrylamide Gel Electrophoresis General Chapter
      • Q4B Annex 11Capillary Electrophoresis General Chapter
      • Q4B Annex 12Analytical Sieving General Chapter
      • Q4B Annex 13Bulk Density and Tapped Density of Powders General Chapter
      • Q4B Annex 14Bacterial Endotoxins Test General Chapter
      • Q4B FAQsFrequently Asked Questions

    Quality of Biotechnological Products Q5A - Q5E



      • Q5A(R1)Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal OriginQ5A
      • Q5BAnalysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products
      • Q5CStability Testing of Biotechnological/Biological Products
      • Q5DDerivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products
      • Q5EComparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process
     Specifications Q6A- Q6B



      • Q6ASpecifications : Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
      • Q6BSpecifications : Test Procedures and Acceptance Criteria for Biotechnological/Biological Products

    Good Manufacturing Practice Q7



      • Q7Good Manufacturing Practice Guide for Active Pharmaceutical IngredientsQ7A
      • Q7 Q&AsQuestions and Answers: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

    Pharmaceutical Development Q8



      • Q8(R2)Pharmaceutical Development
      • Q8/9/10 Q&AsR4Q8/Q9/Q10 - Implementation
    Quality Risk Management Q9



      • Q9Quality Risk Management
      • Q8/9/10 Q&AsR4Q8/Q9/Q10 - Implementation
     

    Pharmaceutical Quality System Q10



      • Q10Pharmaceutical Quality System
      • Q8/9/10 Q&AsR4Q8/Q9/Q10 - Implementation

    Development and Manufacture of Drug Substances Q11



    Q11Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)
    Finalised Guideline:
    May 2012




    For download all files click here Zip with all ICH Quality Guidelines in word format

ICH Quality Guidelines Overview

Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.

  • Stability Q1A - Q1F

  • Analytical Validation Q2

  • Impurities Q3A - Q3D

  • Pharmacopoeias Q4 - Q4B

  • Quality of Biotechnological Products Q5A - Q5E

  • Specifications Q6A- Q6B

  • Good Manufacturing Practice Q7

  • Pharmaceutical Development Q8

  • Quality Risk Management Q9

  • Pharmaceutical Quality System Q10

  • Development and Manufacture of Drug Substances Q11

  • Cross-cutting Topics

ICH Guidelines types


The ICH topics are divided into four categories and ICH topic codes are assigned according to these categories.

Quality Guidelines

Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.

Safety Guidelines

ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years.

Efficacy Guidelines

The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/genomics techniques to produce better targeted medicines.

Multidisciplinary Guidelines

Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).

About and history of ICH guidelines




 

 

 

History

The Need to Harmonise


The realisation that it was important to have an independent evaluation of medicinal products before they are allowed on the market was reached at different times in different regions. However in many cases the realisation was driven by tragedies, such as that with thalidomide in Europe in the 1960s.
For most countries, whether or not they had initiated product registration controls earlier, the 1960s and 1970s saw a rapid increase in laws, regulations and guidelines for reporting and evaluating the data on safety, quality and efficacy of new medicinal products. The industry, at the time, was becoming more international and seeking new global markets, however the divergence in technical requirements from country to country was such that industry found it necessary to duplicate many time-consuming and expensive test procedures, in order to market new products, internationally.
The urgent need to rationalise and harmonise regulation was impelled by concerns over rising costs of health care, escalation of the cost of R&D and the need to meet the public expectation that there should be a minimum of delay in making safe and efficacious new treatments available to patients in need.

Initiation of ICH

Harmonisation of regulatory requirements was pioneered by the European Community (EC), in the 1980s, as the EC (now the European Union) moved towards the development of a single market for pharmaceuticals. The success achieved in Europe demonstrated that harmonisation was feasible. At the same time there were bilateral discussions between Europe, Japan and the US on possibilities for harmonisation. It was, however, at the WHO Conference of Drug Regulatory Authorities (ICDRA), in Paris, in 1989, that specific plans for action began to materialise. Soon afterwards, the authorities approached IFPMA to discuss a joint regulatory-industry initiative on international harmonisation, and ICH was conceived.
The birth of ICH took place at a meeting in April 1990, hosted by EFPIA in Brussels. Representatives of the regulatory agencies and industry associations of Europe, Japan and the US met, primarily, to plan an International Conference but the meeting also discussed the wider implications and terms of reference of ICH.
At the first ICH Steering Committee (SC) meeting of ICH the Terms of Reference were agreed and it was decided that the Topics selected for harmonisation would be divided into Safety, Quality and Efficacy to reflect the three criteria which are the basis for approving and authorising new medicinal products.

The Evolution of ICH

For two decades the ICH process has achieved much success. This success is attributed not only to a process of scientific consensus developed between industry and regulatory experts, but also to the commitment of the regulatory parties to implement the ICH Tripartite Harmonised Guidelines and recommendations.
Since ICH's inception in 1990, the ICH process has gradually evolved. ICH's first decade saw significant progress in the development of Tripartite ICH Guidelines on Safety, Quality and Efficacy topics. Work was also undertaken on a number of important multidisciplinary topics, which included MedDRA (Medical Dictionary for Regulatory Activities) and the CTD (Common Technical Document). As ICH started into a new millennium, the need to expand communication and dissemination of information on ICH Guidelines with non-ICH regions became a key focus. Attention was also directed towards facilitating the implementation of ICH Guidelines in ICH's own regions.
Throughout the second decade the development of ICH Guidelines continued, but with more attention given to the need to maintain already existing Guidelines as science and technology continued to evolve. The need to leverage with other organisations was also acknowledged, particularly for the development of electronic standards. The SC recognised the benefits afforded by collaboration with Standards Development Organisations, not only from the perspective of having a larger available pool of technical expertise, but also the opportunity to progress ICH standards as global standards.
Entering into its third decade of activity, ICH's attention is directed towards extending the benefits of harmonisation beyond the ICH regions. Training, as well as active participation of non-ICH regions in guideline development, are seen as key in this effort.

Biopharma-guidelines




Welcome to the great scientist’s those who had the science degrees and working for medicinal product development and manufacturing. The Biopharma-guidelines web portal is the one of the international platform to learn the regulatory pharmaceutical guidelines where the global guidelines available.
You can have the ICH, WHO, ISO, US-FDA, TGA, MHRA, MCC, MCA, EU, MEDSAFE, GCC, PDMA, IPEQ  and PDA etc.

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | cheap international calls